Osteonic’s Q1 Net Profit Surges 250% on Expanded U.S. Sports Medicine Exports
Osteonic, a company specializing in orthopedic implants, posted significant growth in both sales and profitability in the first quarter of this year.
On May 14, Osteonic announced its consolidated first-quarter results, reporting sales of KRW 12.9 billion, operating profit of KRW 2.3 billion, and net profit of KRW 2.7 billion.
Sales increased by 35.4% compared to the same period last year, while operating profit rose by 55.7% and net profit surged by 248.4%. Notably, Osteonic achieved sales and operating profit similar to the levels typically recorded in the fourth quarter, which is usually the company’s strongest season, despite the impact of the seasonal off-peak period.
The sports medicine business segment showed particularly strong growth in these results. The sports medicine division recorded sales of KRW 5.6 billion in the first quarter of this year, more than doubling compared to the same period last year.
Breaking it down further, domestic sales increased by 18%, while exports soared by 729%. The company explained that the increase in shipments of sports medicine products supplied to the United States on an ODM basis for Zimmer Biomet, a global orthopedic medical device company, was the main driver of this growth.
Osteonic signed an exclusive global supply agreement for sports medicine products with Zimmer Biomet, the world’s second-largest orthopedic medical device company, in 2020. Since May last year, the company has begun full-scale supply to the U.S. market.
The securities industry has also given a positive assessment of Osteonic’s growth potential. SK Securities forecasts Osteonic’s 2026 annual results at KRW 60.1 billion in sales and KRW 14 billion in operating profit, and has issued a ‘BUY’ investment rating with a target price of KRW 10,300.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This performance is seen as evidence that Osteonic’s global growth strategy is bearing fruit, supported by the expansion of its supply in the U.S. sports medicine market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.